Pneumococcal Vaccines
28
3
6
16
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Published Results
12 trials with published results (43%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 28 trials
100.0%
+13.5% vs benchmark
57%
16 trials in Phase 3/4
75%
12 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (28)
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
Opportunistic Pneumococcal Immunisation Trial in MALnutrition
Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans
Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults
Reminder Emails to Improve Pneumococcal Vaccine Completion at 12 Months of Age
Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
Evaluation of the Non-Inferiority of a 12-Valent Pneumococcal Conjugate Vaccine in Healthy Children in Brazil.
Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses